SNPX Synaptogenix Inc.: ערך חשבונאי למניה

Synaptogenix, Inc. (SNPX) profitability relies on a closed patent perimeter for briostatin-1, which binds clinics to its protocols. The historical book value dynamics on the GURU.Markets terminal chart demonstrate a capitalization where the 0.00 metric confirms the current level. Synaptogenix, Inc. (SNPX) is developing a memory recovery system to combat dementia, while the current pipeline is focused on preparing new trial phases for its key molecule.

Book value per share reflects the portion of equity attributable to a single security after deducting all liabilities from total assets. The trend in book value per share allows for the tracking of resource preservation at Synaptogenix, Inc. (SNPX), which is critical for a biopharmaceutical brand investing in costly research into neuroregenerative drugs for the therapy of Alzheimer's disease.